TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

Growing enthusiasm around next-generation checkpoint target TIGIT fueled a £56 million ($70 million) raise for Mereo, which plans to start a Phase Ib trial of etigilimab in 4Q20.

Shares of the London-based biotech added $1.09 (56%) to $3.05 on NASDAQ Thursday, and rose 106% to 49.50p on the LSE...